Covalent small molecule inhibitors of Ca2+-bound S100B

Biochemistry

Volumn 53, Issue 42, 2014, Pages 6628-6640

  Cavalier, Michael C ^a   Pierce, Adam D ^a   Wilder, Paul T ^a   Alasady, Milad J ^a   Hartman, Kira G ^a   Neau, David B ^b   Foley, Timothy L ^c   Jadhav, Ajit ^c   Maloney, David J ^c   Simeonov, Anton ^c   Toth, Eric A ^a   Weber, David J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; CELL DEATH; DERMATOLOGY; MOLECULES; NUCLEAR MAGNETIC RESONANCE; ONCOLOGY; PROTEINS; RESTORATION; TUMORS;

COMPETITION ASSAYS; CRYSTALLOGRAPHIC STRUCTURE; FLUORESCENCE POLARIZATION; MALIGNANT MELANOMA; SMALL INTERFERING RNA; SMALL MOLECULE INHIBITOR; STRUCTURE ACTIVITY RELATIONSHIPS; TUMOR SUPPRESSION;

BINDING SITES;

ANTINEOPLASTIC AGENT; CALCIUM; CYSTEINE; PROTEIN P53; PROTEIN S100B; PROTEIN S100B INHIBITOR; SMALL INTERFERING RNA; TETRAMER; TUMOR MARKER; UNCLASSIFIED DRUG; 3,4-DIMETHOXYDALBERGIONE; BENZOPHENANTHRIDINE DERIVATIVE; BENZOQUINONE DERIVATIVE; CHELERYTHRINE; DISULFIRAM; DITERPENE; DIVALENT CATION; PROTEIN BINDING; RUBESCENSINE A;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL GROWTH; CONTROLLED STUDY; COVALENT BOND; CRYSTALLOGRAPHY; DRUG BINDING SITE; DRUG DESIGN; FLUORESCENCE COMPETITION COMPETITION ASSAY; FLUORESCENCE POLARIZATION; GENE PRODUCT; MELANOMA; MELANOMA CELL; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BOVINAE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PROTEIN CONFORMATION; RAT; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZOPHENANTHRIDINES; BENZOQUINONES; BINDING SITES; CALCIUM; CATIONS, DIVALENT; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DISULFIRAM; DITERPENES; HUMANS; MELANOMA; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RATS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84908276620     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi5005552     Document Type: Article

References (75)

1. Kwong, L. N. and Davies, M. A. (2014) Targeted therapy for melanoma: Rational combinatorial approaches Oncogene 33, 1-9
2. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., and Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366, 2443-2454
3. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y., Artis, D. R., Schlessinger, J., Su, F., Higgins, B., Iyer, R., D'Andrea, K., Koehler, A., Stumm, M., Lin, P. S., Lee, R. J., Grippo, J., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., Chapman, P. B., Flaherty, K. T., Xu, X., Nathanson, K. L., and Nolop, K. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467, 596-599
4. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., and Chapman, P. B. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363, 809-819
5. Espinosa, E., Grob, J. J., Dummer, R., Rutkowski, P., Robert, C., Gogas, H., Kefford, R., Eggermont, A. M., Martin Algarra, S., Hauschild, A., and Schadendorf, D. (2014) Treatment Algorithms in Stage IV Melanoma American Journal of Therapeutics DOI: 10.1097/MJT.0b013e31829e885c
6. Gogas, H., Abali, H., Ascierto, P. A., Demidov, L., Pehamberger, H., Robert, C., Schachter, J., Eggermont, A. M., Hauschild, A., and Espinosa, E. (2013) Who Benefits Most From Adjuvant Interferon Treatment for Melanoma? American Journal of Therapeutics DOI: 10.1097/MJT.0b013e31829e883d
7. Jang, S. and Atkins, M. B. (2013) Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 14, e60-e69
8. Marcus, D. M., Lowe, M., Khan, M. K., Lawson, D. H., Crocker, I. R., Shelton, J. W., Melton, A., Maynard, N., Delman, K. A., Carlson, G. W., and Rizzo, M. (2013) Prognostic Factors for Overall Survival After Radiosurgery for Brain Metastases From Melanoma Am. J. Clin. Oncol. DOI: 10.1097/COC.0b013e318280d7be
9. Kashani-Sabet, M. (2014) Molecular markers in melanoma Br. J. Dermatol. 170, 31-35
10. Riechers, A. and Bosserhoff, A. K. (2014) Melanoma inhibitory activity in melanoma diagnostics and therapy: A small protein is looming large Exp. Dermatol. 23, 12-14
11. El Hajj, P., Journe, F., Wiedig, M., Laios, I., Sales, F., Galibert, M. D., Van Kempen, L. C., Spatz, A., Badran, B., Larsimont, D., Awada, A., and Ghanem, G. (2013) Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients Br. J. Cancer 108, 1641-1647
12. Henry, L., Fabre, C., Guiraud, I., Bastide, S., Fabbro-Peray, P., Martinez, J., Lavabre-Bertrand, T., Meunier, L., and Stoebner, P. E. (2013) Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein Int. J. Cancer 133, 142-148
13. Wieder, H. A., Tekin, G., Rosenbaum-Krumme, S., Klode, J., Altenbernd, J., Bockisch, A., and Nagarajah, J. (2013) 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma Nuklearmedizin 52, 198-203
14. Schiltz, P. M., Dillman, R. O., Korse, C. M., Cubellis, J. M., Lee, G. J., and De Gast, G. C. (2008) Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells Cancer Biother. Radiopharm. 23, 214-221
15. O'Rourke, M. G., Johnson, M., Lanagan, C., See, J., Yang, J., Bell, J. R., Slater, G. J., Kerr, B. M., Crowe, B., Purdie, D. M., Elliott, S. L., Ellem, K. A., and Schmidt, C. W. (2003) Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine Cancer Immunol. Immunother. 52, 387-395
16. Hartman, K. G., McKnight, L. E., Liriano, M. A., and Weber, D. J. (2013) The evolution of S100B inhibitors for the treatment of malignant melanoma Future Med. Chem. 5, 97-109
17. Lin, J., Yang, Q., Wilder, P. T., Carrier, F., and Weber, D. J. (2010) The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma J. Biol. Chem. 285, 27487-27498
18. Lin, J., Yang, Q., Yan, Z., Markowitz, J., Wilder, P. T., Carrier, F., and Weber, D. J. (2004) Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells J. Biol. Chem. 279, 34071-34077
19. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S., and Lawrence, J. J. (1992) Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein Proc. Natl. Acad. Sci. U.S.A. 89, 11627-11631
20. 2+-bound rat S100B (ββ) upon binding to a peptide derived from the C-terminal regulatory domain of p53 Protein Sci. 8, 1743-1751
21. Rustandi, R. R., Baldisseri, D. M., and Weber, D. J. (2000) Structure of the negative regulatory domain of p53 bound to S100B(ββ) Nat. Struct. Biol. 7, 570-574
22. 2+-dependent interaction of S100B(ββ) with a peptide derived from p53 Biochemistry 37, 1951-1960
23. 2+-dependent manner Protein Sci. 7, 794-798
24. Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carrier, F. (2001) Inhibition of p53 transcriptional activity by the S100B calcium-binding protein J. Biol. Chem. 276, 35037-35041
25. Weber, D. J., Rustandi, R. R., Carrier, F., and Zimmer, D. B. (2000) Interaction of dimeric S100B(ββ) with the tumor suppressor protein: A model for Ca-dependent S100-target protein interactions. In The molecular basis of calcium action in biology and medicine (Pochet, R., Ed.) pp 469-487, Kluwer Academic Publishers, Dordrecht, The Netherlands.
26. Hussein, M. R., Haemel, A. K., and Wood, G. S. (2003) p53-related pathways and the molecular pathogenesis of melanoma Eur. J. Cancer Prev. 12, 93-100
27. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., and Lane, D. P. (2009) Awakening guardian angels: Drugging the p53 pathway Nat. Rev. Cancer 9, 862-873
28. Smith, J., Stewart, B. J., Glaysher, S., Peregrin, K., Knight, L. A., Weber, D. J., and Cree, I. A. (2010) The effect of pentamidine on melanoma ex vivo Anticancer Drugs 21, 181-185
29. Zimmer, D. B., Lapidus, R. G., and Weber, D. J. (2013) In vivo screening of S100B inhibitors for melanoma therapy Methods Mol. Biol. 963, 303-317
30. Jochemsen, A. G. (2014) Reactivation of p53 as therapeutic intervention for malignant melanoma Curr. Opin. Oncol. 26, 114-119
31. Markowitz, J., Chen, I., Gitti, R., Baldisseri, D. M., Pan, Y., Udan, R., Carrier, F., MacKerell, A. D., Jr., and Weber, D. J. (2004) Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction J. Med. Chem. 47, 5085-5093
32. 2+ as examined by NMR and X-ray crystallography J. Mol. Biol. 396, 1227-1243
33. Charpentier, T. H., Wilder, P. T., Liriano, M. A., Varney, K. M., Zhong, S., Coop, A., Pozharski, E., MacKerell, A. D., Jr., Toth, E. A., and Weber, D. J. (2009) Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography Biochemistry 48, 6202-6212
34. McKnight, L. E., Raman, E. P., Bezawada, P., Kudrimoti, S., Wilder, P. T., Hartman, K. G., Godoy-Ruiz, R., Toth, E. A., Coop, A., Mackerell, A. D., Jr., and Weber, D. J. (2012) Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B ACS Med. Chem. Lett. 3, 975-979
35. Wilder, P. T., Charpentier, T. H., Liriano, M. A., Gianni, K., Varney, K. M., Pozharski, E., Coop, A., Toth, E. A., Mackerell, A. D., and Weber, D. J. (2010) In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction Int. J. High Throughput Screening 2010, 109-126
36. Charpentier, T. H., Wilder, P. T., Liriano, M. A., Varney, K. M., Pozharski, E., MacKerell, A. D., Jr., Coop, A., Toth, E. A., and Weber, D. J. (2008) Divalent metal ion complexes of S100B in the absence and presence of pentamidine J. Mol. Biol. 382, 56-73
37. Drohat, A. C., Amburgey, J. C., Abildgaard, F., Starich, M. R., Baldisseri, D., and Weber, D. J. (1996) Solution structure of rat apo-S100B(ββ) as determined by NMR spectroscopy Biochemistry 35, 11577-11588
38. 15N NMR assignments and solution secondary structure of rat Apo-S100β J. Biomol. NMR 6, 171-179
39. Kabsch, W. (2010) Xds Acta Crystallogr. D66, 125-132
40. Soltis, S. M., Cohen, A. E., Deacon, A., Eriksson, T., Gonzalez, A., McPhillips, S., Chui, H., Dunten, P., Hollenbeck, M., Mathews, I., Miller, M., Moorhead, P., Phizackerley, R. P., Smith, C., Song, J., van dem Bedem, H., Ellis, P., Kuhn, P., McPhillips, T., Sauter, N., Sharp, K., Tsyba, I., and Wolf, G. (2008) New paradigm for macromolecular crystallography experiments at SSRL: Automated crystal screening and remote data collection Acta Crystallogr. D64, 1210-1221
41. Cohen, A. E., Ellis, P. J., Miller, M. D., Deacon, A. M., and Phizackerley, R. P. (2002) An automated system to mount cryo-cooled protein crystals on a synchrotron beamline, using compact sample cassettes and a small-scale robot J. Appl. Crystallogr. 35, 720-726
42. McPhillips, T. M., McPhillips, S. E., Chiu, H. J., Cohen, A. E., Deacon, A. M., Ellis, P. J., Garman, E., Gonzalez, A., Sauter, N. K., Phizackerley, R. P., Soltis, S. M., and Kuhn, P. (2002) Blu-Ice and the Distributed Control System: Software for data acquisition and instrument control at macromolecular crystallography beamlines J. Synchrotron Radiat. 9, 401-406
43. Gonzalez, A. and Tsai, Y. (2010) AUTOXDS, Stanford University, Stanford, CA.
44. Leslie, A. G. W. and Powell, H. R. (2007) Processing Diffraction Data with Mosflm Evolving Methods for Macromolecular Crystallography 245, 41-51
45. Project, C. C. (1994) The CCP4 Suite: Programs for Protein Crystallography Acta Crystallogr. D50, 760-63
46. Gibson, R. P., Tarling, C. A., Roberts, S., Withers, S. G., and Davies, G. J. (2004) The donor subsite of trehalose-6-phosphate synthase: Binary complexes with UDP-glucose and UDP-2-deoxy-2-fluoro-glucose at 2 Å resolution J. Biol. Chem. 279, 1950-1955
47. Matsumura, H., Shiba, T., Inoue, T., Harada, S., and Kai, Y. (1998) A novel mode of target recognition suggested by the 2.0 Å structure of holo S100B from bovine brain Structure 6, 233-241
48. Mccoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software J. Appl. Crystallogr. 40, 658-674
49. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D66, 213-221
50. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot Acta Crystallogr. D66, 486-501
51. Afonine, P. V., Grosse-Kunstleve, R. W., and Adams, P. D. (2005) The Phenix Refinement Framework,. CCP4 Newsletter, Vol. 42, Contribution 8, Daresbury Laboratory, Warrington, U.K.
52. Hartman, K. G., Vitolo, M. I., Pierce, A. D., Fox, J. M., Shapiro, P., Martin, S. S., Wilder, P. T., and Weber, D. J. (2014) Complex Formation between S100B Protein and the p90 Ribosomal S6 Kinase (RSK) in Malignant Melanoma Is Calcium-dependent and Inhibits Extracellular Signal-regulated Kinase (ERK)-mediated Phosphorylation of RSK J. Biol. Chem. 289, 12886-12895
53. Bachman, K. E., Sager, J., Cheong, I., Catto, M., Bardelli, A., Park, B. H., Vogelstein, B., Carotti, A., Kinzler, K. W., and Lengauer, C. (2005) Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells Mol. Cancer Ther. 4, 1026-1030
54. Myers, M. A. (1998) Direct measurement of cell numbers in microtitre plate cultures using the fluorescent dye SYBR green I J. Immunol. Methods 212, 99-103
55. Sauna, Z. E., Peng, X. H., Nandigama, K., Tekle, S., and Ambudkar, S. V. (2004) The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1) Mol. Pharmacol. 65, 675-684
56. 2+-binding site on S100B as determined by NMR spectroscopy and site-directed mutagenesis Biochemistry 42, 13410-13421
57. Wilder, P. T., Varney, K. M., Weiss, M. B., Gitti, R. K., and Weber, D. J. (2005) Solution structure of zinc- and calcium-bound rat S100B as determined by nuclear magnetic resonance spectroscopy Biochemistry 44, 5690-5702
58. Cremer, D., Hausen, B. M., and Schmalle, H. W. (1987) Toward a rationalization of the sensitizing potency of substituted p-benzoquinones: Reaction of nucleophiles with p-benzoquinones J. Med. Chem. 30, 1678-1681
59. Mather, B. D., Viswanathan, K., Miller, K. M., and Long, T. E. (2006) Michael addition reactions in macromolecular design for emerging technologies Prog. Polym. Sci. 31, 487-531
60. Lou, H., Ookhtens, M., Stolz, A., and Kaplowitz, N. (2003) Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells Am. J. Physiol. 285, G1335-G1344
61. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. (2003) Cancer statistics, 2003 Ca-Cancer J. Clin. 53, 5-26
62. Abraha, H. D., Fuller, L. C., Du Vivier, A. W., Higgins, E. M., and Sherwood, R. A. (1997) Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma Br. J. Dermatol. 137, 381-385
63. Banfalvi, T., Gilde, K., Gergye, M., Boldizsar, M., Kremmer, T., and Otto, S. (2003) Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma Eur. J. Cancer 39, 164-169
64. Buer, J., Probst, M., Franzke, A., Duensing, S., Haindl, J., Volkenandt, M., Wittke, F., Hoffmann, R., Ganser, A., and Atzpodien, J. (1997) Elevated serum levels of S100 and survival in metastatic malignant melanoma Br. J. Cancer 75, 1373-1376
65. Djukanovic, D., Hofmann, U., Sucker, A., Rittgen, W., and Schadendorf, D. (2000) Comparison of S100 protein and MIA protein as serum marker for malignant melanoma Anticancer Res. 20, 2203-2207
66. Guo, H. B., Stoffel-Wagner, B., Bierwirth, T., Mezger, J., and Klingmuller, D. (1995) Clinical significance of serum S100 in metastatic malignant melanoma Eur. J. Cancer 31A, 1898-1902
67. Karnell, R., von Schoultz, E., Hansson, L. O., Nilsson, B., Arstrand, K., and Kagedal, B. (1997) S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma Melanoma Res. 7, 393-399
68. Mohammed, A. A. and Januzzi, J. L., Jr. (2010) Clinical applications of highly sensitive troponin assays Cardiol. Rev. 18, 12-19
69. Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division Cell 88, 323-331
70. Kohler, J. and Schuler, M. (2014) LUX-Lung 3: Redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer Future Oncol. 10, 533-540
71. Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frodin, M., and Taunton, J. (2012) Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 8, 471-476
72. Erlanson, D. A., Wells, J. A., and Braisted, A. C. (2004) Tethering: Fragment-based drug discovery Annu. Rev. Biophys. Biomol. Struct. 33, 199-223
73. Potashman, M. H. and Duggan, M. E. (2009) Covalent modifiers: An orthogonal approach to drug design J. Med. Chem. 52, 1231-1246
74. Lim, S. Y., Raftery, M. J., Goyette, J., Hsu, K., and Geczy, C. L. (2009) Oxidative modifications of S100 proteins: Functional regulation by redox J. Leukocyte Biol. 86, 577-587
75. Meghnani, V., Vetter, S. W., and Leclerc, E. (2014) RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line Biochim. Biophys. Acta 1842, 1017-1027